Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR?
- CARVALHO, Giovanna M. C.
- OLIVEIRA, Vinicius R.
- SOARES, Raquel M.
- AZEVEDO, Sandra M. F. O.
- LIMA, Lidia M.
- BARREIRO, Eliezer J.
- VALENCA, Samuel S.
- SALDIVA, Paulo H. N.
- FAFFE, Debora S.
- ZIN, Walter A.
DOIAbstract
The treatment of microcystin-LR (MCYST-LR)-induced lung inflammation has never been reported Hence. LASSBio 596, an anti-Inflammatory drug candidate, designed as symbiotic agent that modulates TNF-alpha levels and inhibits phosphodiesterase types 4 and 5, or dexamethasone were tested in this condition Swiss mice were intraperitoneally (i p) injected with 60 mu l of saline (CTRL) or a sub-lethal dose of MCYST-LR (40 mu g/kg). 6 h later they were treated (i p.) with saline (TOX), LASSB10 596 (10 mg/kg, L596), or dexamethasone (1 mg/kg, 0.1 mL, DEXA). 8 h after MCYST-LR injection, pulmonary mechanics were determined, and lungs and livers prepared for histopathology, biochemical analysis and quantification of MCYST-LR. TOX showed significantly ...
Add to ORKG